Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
MediXall Group. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
MediXall Group's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MediXall Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Healthcare Services industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare MediXall Group's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare MediXall Group's earnings growth to the United States of America market average as no estimate data is available.
Unable to compare MediXall Group's revenue growth to the United States of America market average as no estimate data is available.
Unable to determine if MediXall Group is high growth as no earnings estimate data is available.
Unable to determine if MediXall Group is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access MediXall Group's filings and announcements here.
MediXall Group's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Neil Swartz, CPA, serves as the Chief Executive Officer at MediXall Group, Inc and served as its President. Mr. Swartz served as Interim Chief Executive Officer at MediXall Group, Inc since December 28, 2016 and served as its Interim President. Mr. Swartz has been the Interim Chief Executive Officer and Interim President at Continental Rail Corp. since December 28, 2016. Mr. Swartz has been the President of TurnKey Capital Inc. since March 14, 2016 and has been its Chief Executive Officer since October 31, 2014. Mr. Swartz has been President and Chief Executive Officer of Train Travel Holdings, Inc. (TBG Holdings Corp) since 2009 and serves as its Director. He serves as Chief Executive Officer of TBG Investment Partners, LLLP. He also serves as the Chairman and Chief Executive Officer of Monkey Rock Group, Inc. He is a Co-founder of Visiomed International, Inc. Mr. Swartz served as Chairman and Director of MediXall Group, Inc from July 29 to December 11 in 2013. Mr. Swartz served as the President, Chief Executive Officer and Director of TurnKey Capital Inc. from January 23, 2014 to October 3, 2014. Mr. Swartz's business experience includes positions such as managing director of Sunbelt South East Florida, LLC, a business brokerage of mergers and acquisitions firm with 350 offices worldwide. Prior to TBG and Sunbelt, Mr. Swartz was Chairman and Chief Executive Officer of a software company, which he took public on the NASDAQ Small Cap Market. He served as Chief Executive Officer and Director of NetSpace International Holdings, Inc. until August 2007. He served as Chief Financial Officer and Director of Kaya Holdings, Inc. until August 2011. He has been Chairman of the Board of Directors at MediXall Group, Inc. since May 9, 2018. He served as Chairman of Continental Rail Corp. since July 29, 2013 until December 11, 2013. He serves as Director of TurnKey Capital Inc. He served as a Director of TurnKey Capital Inc. since October 31, 2014 until January 15, 2016. Mr. Swartz is a CPA and received his BS degree in Accounting from Northeastern University. He is a member of the American Institute of Certified Public Accountants and the Pennsylvania Institute of Certified Public Accountants.
Neil's compensation has been consistent with company performance over the past year, both up more than 20%.
Neil's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the MediXall Group management team is about average.
Chairman & CEO
Executive Vice President
Senior Vice President of Laboratory Services
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the MediXall Group board of directors is less than 3 years, this suggests a new board.
MediXall Group, Inc. operates as a healthcare incubator for development-stage healthcare technology companies in the United States. The company operates an electronic healthcare platform, where patients/clients can shop for their own medical services; diagnostic procedures and services; and medical equipment and devices to consumers and corporations, such as self-insured and private insurance companies. It also provides medical procedure, cosmetic and elective procedure, commercial, and medical accounts receivable loans to the healthcare sector. MediXall Group, Inc. is based in Fort Lauderdale, Florida.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.